Area of research
Pathology and Forensic Medicine · Molecular Biology
Research interest
Research interests include Systemic Sclerosis and Related Diseases, Connective Tissue Growth Factor Research, Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis, and Inflammatory Myopathies and Dermatomyositis.
Lysosomal dysfunction and inflammatory sterol metabolism in pulmonary arterial hypertension
An international perspective on the future of systemic sclerosis research
Systems-based identification of the Hippo pathway for promoting fibrotic mesenchymal differentiation in systemic sclerosis
An integrated cell atlas of the lung in health and disease
Wnt7a deficit is associated with dysfunctional angiogenesis in pulmonary arterial hypertension
GATA6 coordinates cross-talk between BMP10 and oxidative stress axis in pulmonary arterial hypertension
Abstract 17218: CES1 Deficiency is Associated With Metabolic Reprograming and Endothelial Dysfunction in Pulmonary Arterial Hypertension
Biomarkers of haemodynamic severity of systemic sclerosis-associated pulmonary arterial hypertension by serum proteome analysis
Metabolomic Profiles Differentiate Scleroderma-PAH From Idiopathic PAH and Correspond With Worsened Functional Capacity
Integrated Single-Cell Atlas of Endothelial Cells of the Human Lung
B cell signatures and tertiary lymphoid structures contribute to outcome in head and neck squamous cell carcinoma
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report
Frataxin deficiency promotes endothelial senescence in pulmonary hypertension
Chronic lung diseases are associated with gene expression programs favoring SARS-CoV-2 entry and severity
SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues
Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer
Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo‐Controlled Trial in Adults With Systemic Sclerosis
Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial
Proliferating SPP1/MERTK-expressing macrophages in idiopathic pulmonary fibrosis
Shared and distinct mechanisms of fibrosis
Adaptive plasticity of IL-10+ and IL-35+ Treg cells cooperatively promotes tumor T cell exhaustion
Single-cell analysis reveals fibroblast heterogeneity and myofibroblasts in systemic sclerosis-associated interstitial lung disease
Treg Cells Promote the SREBP1-Dependent Metabolic Fitness of Tumor-Promoting Macrophages via Repression of CD8+ T Cell-Derived Interferon-γ
Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase <scp>II</scp> Investigator‐Initiated, Multicenter, Double‐Blind, Randomized, Placebo‐Controlled Trial
A Bayesian mixture model for clustering droplet-based single-cell transcriptomic data from population studies
Randomised, double-blind, placebo-controlled trial of IL1-trap, rilonacept, in systemic sclerosis. A phase I/II biomarker trial.
PubMed 2019cited by 38position: last
A multicenter randomized, double-blind, placebo-controlled pilot study to assess the efficacy and safety of riociguat in systemic sclerosis-associated digital ulcers
OP0068 ABATACEPT IN EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS— RESULTS OF A PHASE 2 INVESTIGATOR-INITIATED, MULTICENTER, DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED TRIAL
Single Cell RNA Sequencing Identifies HSPG2 and APLNR as Markers of Endothelial Cell Injury in Systemic Sclerosis Skin
Skin Gene Expression Is Prognostic for the Trajectory of Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis